| Name | Title | Contact Details |
|---|
Avellino is a global leader in precision medicine, focused on innovative genetic diagnostics, gene therapies, and genetic data for modern eyecare practices.
DotLab is shaping the future of women`s healthcare technology by developing the first test for endometriosis, affecting 1 in 10 women worldwide.
Vium is the first company to create a living informatics platform for preclinical in vivo drug research.
Advitech is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aytu BioScience, Inc. is a specialty healthcare company focused on developing treatments for urological and related conditions. The Company is currently completing Phase 3 clinical development for its lead therapeutic candidate Zertane™, an orally disintegrating tablet (ODT) formulated specifically for the on-demand treatment of premature ejaculation (PE). The Company`s therapeutic pipeline is supported in part by its first-in-class RedoxSYS® System, which provides the only complete assessment of patients` redox status and enables identification of a broad variety of disorders where redox is implicated. Clinical studies are underway utilizing the RedoxSYS system in male fertility. The Company also recently acquired and is commercializing FDA-approved ProstaScint® (capromab pendetide), a radio-labeled monoclonal antibody, that targets Prostate Specific Membrane Antigen (PSMA), a protein uniquely expressed by prostate tissue. The Company`s strategy is to develop its core therapeutic and diagnostic assets while building an innovative pipeline of established marketed products and late-stage development assets.